Moderna MRNA
NASDAQ MRNA
$218.00 -18.50 (-7.82%)
As of: Oct 16, 2026 · 3:59 PM EDT

Moderna (MRNA) Preferred Stock Liabilities (2017)

Updated

Moderna's Preferred Stock Liabilities came in at $1.18 billion for Q4 2017.

Analysis

Moderna (MRNA) Preferred Stock Liabilities (2017) Analysis & Trends

  • Going back by year, Preferred Stock Liabilities was $1.18 billion in FY2016.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,122.91 Bn 1,091.50 Bn 19.71 Bn -
2 Johnson & Johnson 615.09 Bn 533.62 Bn 17.26 Bn -
3 AbbVie 504.75 Bn 477.86 Bn 12.70 Bn -
4 Merck 360.18 Bn 314.55 Bn 12.21 Bn -
5 Novartis Ag 292.05 Bn 256.04 Bn 11.24 Bn -
6 Astrazeneca 256.09 Bn 229.78 Bn 12.86 Bn -
7 Amgen 233.63 Bn 189.02 Bn 7.24 Bn -
8 Gilead Sciences 194.49 Bn 168.69 Bn 6.22 Bn -
9 Pfizer 168.35 Bn 114.99 Bn 10.94 Bn -
10 Moderna 85.93 Bn 65.29 Bn 52.00 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2017 1.18 Bn
API Access

Moderna Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=MRNA&period=max&api_key=YOUR_API_KEY